Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Assets: 2016-2024

Historic Assets for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $220.7 million.

  • Akebia Therapeutics' Assets rose 75.80% to $364.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $364.2 million, marking a year-over-year increase of 75.80%. This contributed to the annual value of $220.7 million for FY2024, which is 8.70% down from last year.
  • As of FY2024, Akebia Therapeutics' Assets stood at $220.7 million, which was down 8.70% from $241.7 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Assets ranged from a high of $644.1 million in FY2020 and a low of $220.7 million during FY2024.
  • Its 3-year average for Assets is $272.8 million, with a median of $241.7 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first crashed by 32.74% in 2022, then grew by 8.70% in 2024.
  • Over the past 5 years, Akebia Therapeutics' Assets (MRY) stood at $644.1 million in 2020, then decreased by 17.82% to $529.3 million in 2021, then plummeted by 32.74% to $356.1 million in 2022, then tumbled by 32.12% to $241.7 million in 2023, then dropped by 8.70% to $220.7 million in 2024.
  • Its last three reported values are $220.7 million in FY2024, $241.7 million for FY2023, and $356.1 million during FY2022.